The Zhitong Finance App learned that TRex Bio Inc., an early-stage biotechnology company focusing on autoimmune and inflammatory diseases, raised US$117 million through an IPO, and the issue price was set at the lower end of its promotion range.

The Zhitong Finance App learned that TRex Bio Inc., an early-stage biotechnology company focusing on autoimmune and inflammatory diseases, raised US$117 million through an IPO, and the issue price was set at the lower end of its promotion range.